Zobrazeno 1 - 10
of 11 544
pro vyhledávání: '"Pegylated Interferon"'
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate. Methods We st
Externí odkaz:
https://doaj.org/article/f055a74a609d4dee91b82fa7e2b7baa9
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-14 (2024)
Abstract Background Hepatitis B surface antigen (HBsAg) loss is regarded as a pivotal criterion for assessing functional cure in patients diagnosed chronic hepatitis B (CHB). We conducted the research to investigate the real-world performance of HBsA
Externí odkaz:
https://doaj.org/article/55082c31e9ca4210a6a6d7c33eaec95e
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 4465-4474 (2024)
Shao-Long Chen,1 Yao-Jie Shen,2 Guo-Zhi Chen1 1Department of Infectious Disease Control and Prevention, Yueqing Center for Disease Control and Prevention, Wenzhou, 325600, People’s Republic of China; 2Department of Infectious Diseases, Huashan Hosp
Externí odkaz:
https://doaj.org/article/d6a0bdea794046588df9fe33e96e607c
Autor:
Anna S. F. Lok
Publikováno v:
Gut and Liver, Vol 18, Iss 4, Pp 593-601 (2024)
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocell
Externí odkaz:
https://doaj.org/article/cf9f566970f640ac8ddce25d7e3a5556
Autor:
Li Yadi, Luo Haiying, Hu Xiaoxia, Gong Jiaojiao, Tan Guili, Luo Huating, Wang Rui, Pang Hao, Yu Renjie, Qin Bo
Publikováno v:
Polish Journal of Microbiology, Vol 73, Iss 2, Pp 217-235 (2024)
Interferon-alpha (IFN-α) is a first-line drug for treating chronic hepatitis B (CHB). Guanylate-binding protein 1 (GBP1) is one of the interferon-stimulating factors, which participates in the innate immunity of the host and plays an antiviral and a
Externí odkaz:
https://doaj.org/article/9dae418c70fe47b6969af8e87be24f0e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveThis meta-analysis aims to assess the efficacy and safety of adding pegylated interferon (Peg-IFN) to long-term nucleos(t)ide analogs (NAs) treatment for achieving functional cure in patients with chronic hepatitis B (CHB).MethodsThis meta-a
Externí odkaz:
https://doaj.org/article/466deaa583fc4833aa14a2769c0af9b9
Autor:
Jian Wang, Zhiyi Zhang, Li Zhu, Qing Zhang, Shaoqiu Zhang, Yifan Pan, Jiacheng Liu, Fei Cao, Tao Fan, Ye Xiong, Shengxia Yin, Xiaomin Yan, Yuxin Chen, Chuanwu Zhu, Jie Li, Xingxiang Liu, Chao Wu, Rui Huang
Publikováno v:
Virulence, Vol 15, Iss 1 (2024)
Predicting hepatitis B surface antigen (HBsAg) clearance is important for chronic hepatitis B (CHB) patients receiving pegylated interferon-alfa (Peg-IFN) therapy. We aimed to determine the predictive value of serum hepatitis B core antibody (anti-HB
Externí odkaz:
https://doaj.org/article/ed01fac239aa4d71bf6287017f84c328
Autor:
Victor de Lédinghen, Claire Fougerou-Leurent, Estelle Le Pabic, Stanislas Pol, Dulce Alfaiate, Karine Lacombe, Marie-Noëlle Hilleret, Caroline Lascoux-Combe, Anne Minello, Eric Billaud, Isabelle Rosa, Anne Gervais, Vlad Ratziu, Nathalie Ganne, Georges-Philippe Pageaux, Vincent Leroy, Véronique Loustaud-Ratti, Philippe Mathurin, Julie Chas, Caroline Jezequel, Sophie Métivier, Jérôme Dumortier, Jean-Pierre Arpurt, Tarik Asselah, Bruno Roche, Antonia Le Gruyer, Marc-Antoine Valantin, Caroline Scholtès, Emmanuel Gordien, Christelle Tual, Amel Kortebi, Fatoumata Coulibaly, Eric Rosenthal, Miroslava Subic-Levrero, Dominique Roulot, Fabien Zoulim, François Raffi, Laurent Alric, Patrick Miailhes, Albert Tran, Christiane Stern, Xavier Causse, Simona Tripon, Ghassan Riachi, Olivier Chazouillères, Armando Abergel, Louis d’Alteroche, Jérôme Gournay, Garance Lagadic, Patrizia Carrieri, Ségolène Brichler, Martin Siguier, Jessica Krause, Juliette Foucher, Souad Ben Ali, Magdalena Meszaros, Anne Varaut, Valérie Canva
Publikováno v:
JHEP Reports, Vol 6, Iss 8, Pp 101057- (2024)
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfe
Externí odkaz:
https://doaj.org/article/9c555ee813a44c469f08eabb29b34b1d
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Chronic hepatitis B (CHB) is a worldwide infectious disease caused by hepatitis B virus (HBV). Optimizing antiviral treatment strategies could improve the functional cure (FC) rate of patients with CHB. This study aims to systematically
Externí odkaz:
https://doaj.org/article/ac9a0f1e46e949588bd2837654353da4
Autor:
Ching-Chu Lo, Wan-Long Chuang, Hsing-Tao Kuo, Wei-Ming Chen, Albert Qin, Chan-Yen Tsai, Yi-Wen Huang, Chi-Yi Chen
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 1, Pp 55-61 (2024)
Aim: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. Its biweekly dosing schema has demonstrated tolerability and clinical efficacy for treating chronic hepatitis in previous clinical studies. This trial evaluates the pharmacoki
Externí odkaz:
https://doaj.org/article/9850b955695541f483e388e3a8fae2e8